Aim: To evaluate the efficacy of course neurotrophic therapy with cerebrolysin in a group of first-degree relatives of Alzheimer's disease (AD) patients who had minimal cognitive dysfunction.
Material And Methods: Sixty-seven relatives (mean age 57.6±14.2 y.o.) received cerebrolysin in the dose of 20 ml/day in intravenous drips in 100 ml isotonic saline. The duration of treatment was 1 month.
Results: The positive effect of course treatment on the CGI was established in 77.6% of the relatives. The scores on the MMSE and MoCA scales were significantly improved in the group with cognitive difficulties objectively confirmed by the clinical/neuropsychological examination (n=27) and in the group without cognitive difficulties (n=40).
Conclusion: The positive effect of cerebrolysin on the cognitive status of the first-degree relatives of AD patients, regardless of their cognitive deficiency, was demonstrated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro201811810130 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Postoperative complications and long-term outcomes after total and subtotal thyroidectomy: a retrospective study.
Sci Rep
January 2025
Cardiothoracic Surgery and Transplant Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
The choice between total thyroidectomy (TT) and subtotal thyroidectomy (STT) can affect postoperative complications and long-term outcomes in these patients. This study aimed to investigate postoperative complications and long-term outcomes in patients who underwent TT and STT. This retrospective study investigated 1.
View Article and Find Full Text PDFAlpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-analysis and Clinical Practice Guideline.
Chest
January 2025
Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Alpha-1-Antitrypsin (A1AT) deficiency is a common hereditary disorder associated with increased risk of developing chronic obstructive pulmonary disease (COPD). Many individuals with severe A1AT deficiency go undiagnosed, or are diagnosed late, and fail to benefit from disease-specific counseling and modifying care. Since the 2012 Canadian Thoracic Society (CTS) A1AT deficiency clinical practice guideline, new approaches to optimal diagnosis using modern genetic testing and studies of A1AT augmentation therapy have been published.
View Article and Find Full Text PDFThe novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease.
Eur J Neurol
February 2025
1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Background: The p.A53T variant in the SNCA gene was considered, until recently, to be the only SNCA variant causing familial Parkinson's disease (PD) in the Greek population. We identified a novel heterozygous p.
View Article and Find Full Text PDFCARP VIII antibody-related autoimmune cerebellar ataxia in a child after infection: a case report.
Front Immunol
January 2025
First Department of Pediatrics, Weifang People's Hospital Affiliated to Shandong Second Medical University, Weifang, China.
Autoimmune cerebellar ataxia (ACA) is a cerebellar syndrome induced by autoimmune reactions and its onset is induced by malignant tumors, prodromic infection, and gluten allergy. Its clinical symptoms include gait disorder, limb ataxia, dysarthria, and dysphagia. According to , the diagnosis of ACA is based on the following points: 1.
View Article and Find Full Text PDFChanges in CD4+CD25HIGH T cells and TGFβ1 levels in different stages of adult-onset type 1 diabetes.
J Med Biochem
November 2024
University of Belgrade, Faculty of Medicine, University Clinical Centre of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade.
Background: Previous studies suggested an important role of impairments in T cell subsets in different stages during type 1 diabetes (T1D) development, while data regarding CD25high T cells and transforming growth factor b1 (TGFβ1), both T regulatory associated, remains controversial. We analyzed the level of (a) CD25high T cells (b) TGFβ1 in 17 first-degree relatives of patients with T1D in stage 1 (FDRs1) (GADA+, IA-2+); 34 FDRs in stage 0 (FDRs0) (GADA, IA-2); 24 recent-onset T1D in insulin-requiring state (IRS); 10 patients in clinical remission (CR); 18 healthy, unrelated controls (CTR).
Methods: T cell subsets were characterized by two-color immunofluorescence staining and flow cytometry; TGFβ1 was determined by ELISA, GADA, and IA-2 by RIA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!